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ABSTRACT 
Purpose: We studied the effects of sacral (S3) nerve stimulation in patients with urge incon- 
tinence due to detrusor instability. 
Materials and Methods: A permanent S3 foramen electrode was implanted in 18 patients 
(average age 46 years) who had shown a good response during temporary stimulation via a 
percutaneously placed wire electrode. Average followup was 29 months. 
Results: The average voiding frequency and pad use per 24 hours decreased significantly. 
Improvement in several urodynamic parameters was noted. The correlation between symptom- 
atic and urodynamic improvement was incomplete. 
Conclusions: Neuromodulation appears to be a valuable treatment option in these patients. 
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Most patients with urge incontinence and idiopathic detru- 
sor instability are initially treated conservatively with blad- 
der retraining, pelvic floor exercises and biofeedback, while 
in the majority this regimen will be supplemented with an- 
ticholinergic drugs. The urinary incontinence guideline panel 
has summarized the literature on results achieved with var- 
ious drugs for urge incontinence, and found that oxybutynin 
and terodiline appeared to be the most effective.’ Subjective 
cure rates of up to 44% over placebo and decreased urinary 
incontinence rates in up to 56% over placebo were achieved 
with these drugs.’ Interestingly, no changes in urodynamic 
parameters were found in well designed drug trials despite 
symptomatic improvement.2J Fortunately, many patients seem to 
be satisfied with a less than optimal result. Patients who do 
not achieve an acceptable Condition remain a therapeutic 
problem and alternative procedures, with variable success 
rates, such as bladder transection, transvesical phenol injec- 
tion of the pelvic plexus, augmentation ileocystoplasty and 
even urinary diversion, are being advocated.4 
Unilateral sacral segmental nerve stimulation by a perma- 
nent foramen S3 electrode (neuromodulation) offers a nonde- 
structive alternative for those whose condition is refractory 
to conservative measures. The aim of this treatment modal- 
ity is to achieve detrusor inhibition by chronic electrical 
stimulation of afferent somatic sacral nerve fibers via an 
implanted electrode coupled to  a subcutaneously placed pulse 
generator. The ratio of this treatment modality is based on 
the existence of spinal inhibitory systems that are capable of 
interrupting a detrusor contraction. Inhibition can be 
achieved by electrical stimulation of afferent anorectal 
branches of the pelvic nerve, afferent sensory fibers in the 
pudendal nerve and muscle afferents from the limbs.”7 Most 
of these branches and fibers reach the spinal cord via the 
dorsal roots of the sacral nerves. Of the sacral nerve roots the 
S3 root is the most practical for use in chronic electrical 
stimulation.8 We evaluate the effectiveness of this treatment 
modality in patients with urge incontinence due to bladder 
instability. 
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MATERIALS AND METHODS 
Six men and 25 women (mean age 46 years) underwent a 
percutaneous test stimulation of the S3 sacral roots.8 Such a 
stimulation test is currently the only method available to 
evaluate whether this treatment option will work in an indi- 
vidual patient. Patients were selected on the basis of 3 crite- 
ria: 1) urge incontinence in combination with urodynamically 
demonstrated detrusor instability refractory to drug treat- 
ment (instability may be idiopathic or neurogenic), 2) a blad- 
der capacity of at least 150 ml. but less than 500 ml. and 3) 
no untreated urinary tract infection, stone disease, diabetes 
mellitus, psychiatric disturbances, pregnancy or cerebrovas- 
cular accident less than 6 months previously, as well as no 
anatomical abnormalities, infection or decubitus a t  the fu- 
ture operative site. 
The initial and baseline diagnostic evaluation included a 
history and physical examination, urinalysis, urine cytology 
studies, plain abdominal x-ray, ultrasound of the kidneys, 
cystoscopy, 2,4-day voiding-incontinence diaries (registering 
pad use, frequency of leaks, voided volume and voiding fie- 
quency) and a video urodynamic examination that included a 
free flow rate determination, filling cystometry at a rate of 80 
ml. per minute and pressure-flow electromyographic studies. 
Filling cystometry studies were performed with the subject in 
the most provocative position, that is standing. The methods, 
units and definitions in relation to the urodynamic studies 
conformed to the standards recommended by the Interna- 
tional Continence Society.9 
Percutaneous test stimulation. This procedure consists of 
acute test stimulation followed by a sub-chronic test phase. 
In acute test stimulation a spinal needle, insulated by a ~ .  
angiographic catheter sheath, is placed percutaneously in the 
left and right 53 foramina and electrically stimulated by an 
external neuro-stimulator. The muscle response, which typ- 
ically is a levator ani contraction and flexion of the great toe 
when S3 is stimulated, is used as a biological marker for 
correct needle placement. Apart from the stimulation of ef- 
ferent (a-motor) fibers, which induce the muscle responses, 
afferent somatic nerve fibers are stimulated to inhibit the 
micturition reflex. The side with the best muscle response 
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dosen for placement of the test electrode. Good muscle re- 
sponses on 1 or both sides were found in all patients. 
In the sub-chronic test phase a %zero steel guide wire is 
wed as a temporary electrode and placed in the left or right 
foramen. The guide wire is introduced into the foramen 
through the angiographic catheter sheath after removal of 
the spinal needle. Subsequently, the guide wire is continu- 
ously stimulated with a nerve stimulator for 3 to 5 days. The 
stimulation parameters used were pulse width 210 Mec., 
frequency 10 pulses per second and amplitude 0.5 to 20 mA. 
m e  patient again kept a voiding-incontinence diary during 
this period. If there was greater than a 50% decrease in the 
number of leakage episodes andlor pads used the test was 
deemed successful and the patient was offered permanent 
implantation. Tests were successful in 19 of 31 patients 
(61%). Because 1 woman refused surgery 18 patients (58%) 
subsequently underwent permanent implantation. 
Implantation. The complete device consisted of a foramen 
electrode connected to a subcutaneously placed pulse gener- 
ator via a lead extension (fig. 1). The initial pulse generator 
was implanted in the first 8 patients and an improved gen- 
erator was implanted in the remainder. The implant proce- 
dure was described in detail by Siegel.10 The initial stimula- 
tion parameters after activation of the pulse generator were 
pulse width 210 psec., frequency 10 or 15 pulses per second 
and mean amplitude 2.7 +- 0.4 volts (standard error). 
Followup studies included voiding-incontinence diaries at 
1, 3, 6, 9, 12, 15, 18 and 24 months, and a complete urody- 
namic examination 6 months after permanent implantation. 
The Mann-Whitney U test was used to compare patient data 
before and after permanent implantation. The level of statis- 
tical significance was set at p <0.05. 
RESULTS 
The characteristics of the patients undergoing implanta- 
tion are summarized in table 1. These patients had long 
histories of incontinence and on average had undergone more 
than 1 operation for the problem. Average followup was 29 
months (13 patients were followed for 2 years or longer). 
The symptomatic results are summarized in table 2. Sig- 
nificant improvements in voiding frequency, average voided 
volume, number of incontinence episodes and number of pads 
used were found. The results at  last followup are comparable 
TABLE 1. Characteristics of 15 uwnen and 3 men undergoing 
implantation 
._____ _ _ _  
Mean 1 range I 
Age (yrs.) 46 (25-65) 
No. previous operations for incontinence:* 
. _ ~ _ _ _ _ _ _ _ _ _ _ _ - ~ - ~ ~  
Bladder dilations excluded 1.1 tQ-2) 
1.9 (0-61 Bladder dilations included 
3.8 (1-111 
Yrs. Dad use 7.5 (1-281 
Yrs. previous drug use for incontinence 
Mos.'followup 29 (7-47) 
* Of 15 women 10 underwent hysterectomy in addition to the operations for 
incontinence 
TABLE 2. Effect of neuromodulation on voidingincontinence diary 
variables for the comparison of data at baselint and at last 
followup in 18 patients 
Mean 2 SEM 
Mean P 
Baseline Test Followup Change Vdue 
Value Period 
No. voidingepi- 15.3% 1.5 8.8 5 0.8 9.4 2 0.6 -5.9 0.0005 
soded24hrs. 
Av. voided vol. (ml.) 127 z 13 179 5 15 178 2 18 +51 0.006 
No. incontinence 7.5 2 0.8 1.3 5 0.3 1.9 2 0.7 -5.6 0.0002 
episoded24 hrs. 
No. padd24 hrs. 6.4 z 0.8 1.6 5 0.3 1.6 f 0.6 -4.8 0.0003 
to those achieved during the sub-chronic test phase, which 
indicates that there is no deterioration in response to stim- 
ulation with time. Partial (a 50 to 90% decrease in pad use 
and/or incontinence episodes) and excellent (greater than a 
90% decrease) results were noted in 4 and 11 patients, re- 
spectively (table 3). Therefore, 15 of 18 patients (83%) were 
treated successfully. Some patients continue to use 1 or 2 
pads per 24 hours despite the fact that they report no incon- 
tinence episodes. Alternatively, some patients reported sev- 
eral episodes of slight leakage but they use only 1 pad per 24 
hours. At last followup 9 of the 18 patients were reported to 
be completely dry (that is no leaks). Of the 13 patients fol- 
lowed for longer than 2 years 6 were reportedly completely 
dry at the last followup visit. The average pretreatment pad 
use in patients who were completely dry at the last followup 
visit was 5.8 per 24 hours compared to 7.7 among those who 
still reported occasional leakage. However, even in the latter 
group the pad use decreased from 7.7 to 3.9 per 24 hours. The 
evolution of pad use in the 13 patients followed for longer 
than 2 years is shown in figure 2. 
The influence of neuromodulation on d y n a m i c  variables 
is summarized in table 4, which shows results of filling cys- 
tometry studies performed with the patient in the most pro- 
vocative position, that is standing. At 6 months statistically 
significant changes were noted, consisting of an increase in 
bladder volume at normal desire from 204 t 34 to 318 2 38 
ml. and a decrease in amplitude of the maximum unstable 
contraction from 40 2 7 to 30 5 9 cm. water. More impor- 
tantly, unstable contractions were no longer detectable in 8 
patients at  6 months, while in the other 10 the average 
bladder volume at  initial and maximum unstable contrac- 
TABLE 3. Results of neuromodulation according to predefined 
criteria in 18 patients 
No. Pta. 
MoreThan 5 O t o 9 0 8  LessThan 
W%Decreaee Decrease 5096Decrease 
(excellent) (oartiall (failed) 
Pad use 11 3 4 - _ _  __. 
Incontinence episodes 10 5 3 
Pad nence us  episodes 
11 4 3 FIG. 1. Position of pulse generator, extension lead and S3 foramen 
electrode in patient with permanently implanted neural prosthesis. 
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FIG. 2. Mean pad use per 24 hours in 13 patients after 2 years. 
Error bars indicate standard error of mean. 
tions increased. However, statistical significance was not 
achieved in this subgroup. 
There was an  incomplete correlation between symptomatic 
and urodynamic changes. Of the 9 patients who were com- 
pletely dry a t  last followup 3 still had urodynamic evidence of 
bladder instability, while 2 of 9 who were not dry a t  last 
followup had a stable bladder. An example of the baseline 
urodynamic study compared to the post-implant filling cys- 
tometry study with electrical stimulation turned on in 1 of 
the patients is shown in figure 3. 
Complications were mild. In 1 patient the electrode had to 
be repositioned twice because of dislocation, while later the 
extension lead had to be exchanged because of a lead frac- 
ture. In 2 patients repositioning of the lead was necessary 
because of dislocation (1) and faulty placement in the fora- 
men during the original implantation (1). One patient com- 
plained of pain at the side of the pulse generator, which 
resolved aRer repositioning the pulse generator away from 
the scar of a previous median laparotomy incision. 
DISCUSSION 
Neuromodulation has been advocated as a treatment op- 
tion for various lower urinary tract dysfunctions, including 
incontinence, urge-frequency syndromes, pain syndromes, 
post-prostatectomy incontinence and urinary retention.11.12 
Beneficial effects in patients with clinical conditions other 
than urge incontinence due to detrusor instability have been 
established in an empirical fashion,13 and still lack a solid 
theoretical background and explanation. So as not to obscure 
the results by inclusion of patients with symptoms that are 
mainly subjective and difficult to quantify, we decided to test 
this new treatment modality in a difficult homogeneous 
group with objectively demonstrable detrusor instability and 
long-standing urge incontinence refractory to drug treat- 
ment. Of the patients who failed the percutaneous test stim- 
ulation 4 have undergone augmentation ileocystoplasty and 
most of the remainder are taking part in clinical trials with 
new drugs. 
Combined with the low complication rate, the 83% success 
rate achieved in the implantation patients is promising (61% 
with greater than a 90% and 228 with a 50 to 90% decrease 
in pad use andor incontinence episodes). This effect appears 
to be durable as evidenced by the late results in the patients 
followed for longer than 2 years. 
A neurophysiological explanation for the effectiveness of thh 
treatment modality in detrusor instability is based on animal 
experiments and electrophysiological studies in humans. Spinal 
inhibitory systems capable of interrupting a detrusor contrac- 
tion can be activated by electrical stimulation of afferent an@ 
redal branches of the pelvic nerve, afferent sensory fibers in the 
pudendal nerve and muscle afferents from the 1imbs.S--7 mer- 
ents from the pelvic floor muscles are without an inhibitory 
effect on the bladder, at least in the cat.14 An important argu- 
ment in favor of the effectiveness of neuromodulation in hu- 
mans is the objectively demonstrable d y n a m i c  improve- 
ment, mainly because such effects are not noted in drug trials. 
Although theoretically there are good explanations for its 
effectiveness, several points still need further clarification 
before neuromodulation can achieve the status of a firmly 
established treatment modality. For instance, in some pa- 
tients it is not beyond doubt that the beneficial results a m  
due to the treatment. One of the patients with long-term 
followup had not used the stimulator for 12 months and haa 
not had relapse since that time. Another patient has not used 
the stimulator for 15 months but she had a more peculiar 
course. ARer initial complete success, leakage recurred after 
6 months. The symptoms did not improve after increasing the 
amplitude of stimulation. One month later she decided to 
switch the stimulator off and surprisingly has remained com- 
pletely dry since that time. Are the results as described in 
these 2 patients due to neuromodulation or do they represent 
variants of the natural history of the disease? Why do not all 
patients with urge incontinence due to an unstable bladder 
who underwent test stimulation react favorably, particularly 
if no neurological deficits have been found? 
A further finding of interest is the discrepancy between the 
symptomatic improvement and the urodynamic findings. The 
symptomatic results are much better than one would expect 
on the basis of the urodynamic data. Standard urodynamic 
studies may possibly be too provocative. Ambulatory moni- 
toring of detrusor pressures may be more informative and 
show better correlations. Proved effectiveness in other pa- 
tients, for example those with detrusor instability due to 
neurogenic causes, would give this treatment modality a 
TABLE 4. Effects of neuromodulation on urodynamic variables for the comparison of baseline and 6-month followup data in 18 patients 
studied in the standing position 
Mean ? SEM 
Baseline Value Followup (stimulation on) 
Mean Change p Value 
. ~ 
Bladder capacity at strong desire (ml.) 318 2 44 402 2 39 + 84 Not significant 
First unstable contraction: 
Bladder vol. at normal desire (ml.) 204 2 34 318 Z 38 +114 0 w11 
- - At vol. (ml.) 253 j: 47 - 
At vol. (ml.)* 206 I 40 258 f 36 - 52 Not signific;%nt 
Detrusor pressure (cm. water) 27 2 5 22 t I - 5  N o t  sgnific:int 
At vol. (ml.) 293 j: 45 - 
At vol. (rn1.P 251 z 40 286 z 41 - ;El Not signifir;inL 
Not siynifirant 
Maximum unstable contraction: 
- - 
Detrusor pressure (em. water) 40 : 7 30 I 9 10 0.03 
~ ~ _ _  Post-void residual (ml. I 87 5 27 68 Z 24 - 19 _________ ~ -. 
* Means of the 10 patients with an unstable bladder at baseline as well as at followup. Although the changes in these patients are I ~ O ~ ~ F ~ ~ ~ I ~ ~ ~ ~ I C I ~ I I \  31gidicant, 
it should be noted that 8 other patients had an unstable bladder at baseline but not at followup. 
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FIG. 3. Urodynamic studies in 45-year-old woman in standing position. Recording before implantation shows detrusor instability (max- 
imum detrusor pressure 94 cm. water) and involuntary leakage of urine at filled bladder volume of approximately 100 ml. Reco in same 
patient 6 months after im lantation clearly shows that electrical stimulation is on during filling phase. No incontinence is n o a l i n i d y ,  
atient is completely d &spite demonstrable unstable contraction (maximum detrusor pressure 24 cm. water) at filled volume of more than 
$00 ml. during this uroypamic study. Pves, intravesical pressure. Pabd, abdominal pressure. P&t, detrusor pressure. Flow, flow rate. EMG, 
electromyography. 
more solid basis. A study in select multiple sclerosis patients 
has been initiated at  our institution. 
CONCLUSIONS 
Neuromodulation is an effective treatment modality in pa- 
tients with idiopathic detrusor instability and urge inconti- 
nence. This technology is a valuable addition to our treat- 
ment options in these difficult patients when conservative 
measures fail. The fact that no irreversible changes to the 
bladder or nerves occur is an advantage of this treatment 
option over alternatives, such as bladder augmentation. Be- 
fore general acceptance of this technology, longer followup in 
patients treated to date is needed. Studies must be done 
comparing groups of patients randomly assigned to undergo 
implantation or no treatment to assess possible spontaneous 
improvements more accurately, as well as studies in patients 
with neurogenic voiding dysfunction, such as those with mul- 
tiple sclerosis. 
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